Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.
|Articles|April 1, 1998
Supplements and Featured Publications
- Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach
- Volume 4
- Issue 4 Suppl
Assessing the Value and Affordability of Cholesterol Reduction in the Managed Care Setting
Advertisement
Articles in this issue
over 28 years ago
Participating Facultyover 28 years ago
Coronary Heart Disease in the United Statesover 28 years ago
Mechanisms of Acute Coronary Eventsover 28 years ago
Primary Preventionover 28 years ago
Pravastatin Event Reduction Analysisover 28 years ago
Secondary Preventionover 28 years ago
Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?over 28 years ago
Methods and Mindsets in Pharmacoeconomicsover 28 years ago
Issues and Controversies in PharmacoeconomicsAdvertisement
Related to this article
Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.
Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.
Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap enrollees relative to non–dually eligible traditional Medicare beneficiaries increased from 2013-2024.
Among the therapeutic alternatives used in Medicare’s drug price negotiations, many were generics or biosimilars, and most differed in mechanistic class from the negotiated drug.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
3
Data Show Upadacitinib Repigments Skin in Nonsegmental Vitiligo
4
Oral Iberdomide May Widen Myeloma Access: Mateo Mejia Saldarriaga, MD
5